Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity
- 20 February 2004
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 202 (4) , 503-510
- https://doi.org/10.1002/path.1536
Abstract
It has been shown previously that osteoblast differentiation and maintenance of bone mass are impaired in endothelial nitric oxide synthase gene knockout mice. The present study shows by analysis of messenger RNA expression that the transcription factor Cbfa-1/Runx-2 and the bone matrix protein osteocalcin, which are fundamental to osteoblast differentiation, are significantly reduced in neonatal calvarial osteoblasts from these gene knockout mice. Expression of these genes could be restored to wild-type levels by exogenous supply of the photoactivatable nitric oxide donor potassium nitrosylpentachlorouthenate, but this was dependent on the timing of its activation and recovery in gene expression was only evident during the latter stages of osteoblast differentiation associated with its mineralizing activity. Calvarial, femoral/pelvic, spinal, and total bone mineral density, together with bone microhardness and expression of osteocalcin in whole femurs, were all reduced significantly in gene knockout mice at 8 weeks of age, but not at 12 weeks, where all of these indices of bone integrity were comparable to wild type. In accordance with these temporal effects, reduced bone mineral density, bone microhardness, and osteocalcin expression could be restored to normal, wild-type values after 21 days in vivo administration of the nitric oxide donor glyceryl trinitrate to 4-week-old endothelial nitric oxide synthase knockout mice, but there was no significant effect in older animals. Taken together, these results further demonstrate the importance of endothelial nitric oxide synthase in the regulation of osteoblast metabolism. In particular, they show that nitric oxide is involved in co-ordinating specific phases of osteoblast differentiation and bone formation: this could be relevant to its therapeutic actions on bone turnover. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopeniaBone, 2003
- Mesenchymal Stem Cells and Osteoblast DifferentiationPublished by Elsevier ,2002
- Endothelial Nitric Oxide Synthase Gene-Deficient Mice Demonstrate Marked Retardation in Postnatal Bone Formation, Reduced Bone Volume, and Defects in Osteoblast Maturation and ActivityThe American Journal of Pathology, 2001
- Nitroglycerin Therapy Is as Efficacious as Standard Estrogen Replacement Therapy (Premarin) in Prevention of Oophorectomy-Induced Bone Loss: A Human Pilot Clinical StudyJournal of Bone and Mineral Research, 2000
- Role of Cbfa1 in osteoblast differentiation and functionSeminars in Cell & Developmental Biology, 2000
- Frequency-Dependent Effect of Nitric Oxide Donor Nitroglycerin on BoneJournal of Bone and Mineral Research, 2000
- Nitric Oxide Modulates Fracture HealingJournal of Bone and Mineral Research, 2000
- Nitric oxide donor alleviates ovariectomy-induced bone lossPublished by Elsevier ,1999
- Nitric oxide and boneJournal of Bone and Mineral Research, 1996
- Hypertension in mice lacking the gene for endothelial nitric oxide synthaseNature, 1995